Kenvue Inc. (NYSE:KVUE) Shares Acquired by William Allan Corp

William Allan Corp grew its position in Kenvue Inc. (NYSE:KVUE) by 16.3% during the 4th quarter, HoldingsChannel.com reports. The fund owned 44,032 shares of the company’s stock after buying an additional 6,173 shares during the quarter. William Allan Corp’s holdings in Kenvue were worth $940,000 at the end of the most recent reporting period.

Other institutional investors have also recently made changes to their positions in the company. Grove Bank & Trust lifted its holdings in Kenvue by 438.4% in the 4th quarter. Grove Bank & Trust now owns 1,163 shares of the company’s stock valued at $25,000 after purchasing an additional 947 shares in the last quarter. Riverview Trust Co acquired a new stake in shares of Kenvue in the third quarter valued at about $30,000. Geneos Wealth Management Inc. purchased a new position in shares of Kenvue in the fourth quarter worth about $29,000. Ashton Thomas Securities LLC acquired a new position in Kenvue during the third quarter worth about $35,000. Finally, Fortitude Family Office LLC boosted its position in Kenvue by 106.6% during the fourth quarter. Fortitude Family Office LLC now owns 1,506 shares of the company’s stock worth $32,000 after acquiring an additional 777 shares during the last quarter. 97.64% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of research analysts have weighed in on KVUE shares. Royal Bank of Canada reissued a “sector perform” rating and issued a $24.00 target price on shares of Kenvue in a research note on Monday. JPMorgan Chase & Co. lifted their price objective on Kenvue from $24.00 to $25.00 and gave the stock an “overweight” rating in a research report on Friday, October 11th. Piper Sandler raised Kenvue from a “neutral” rating to an “overweight” rating and raised their target price for the stock from $21.00 to $26.00 in a research note on Monday, January 6th. Citigroup reduced their price target on Kenvue from $25.00 to $21.00 and set a “neutral” rating on the stock in a report on Wednesday, January 15th. Finally, UBS Group dropped their price objective on shares of Kenvue from $24.00 to $23.00 and set a “neutral” rating for the company in a report on Thursday, January 16th. One equities research analyst has rated the stock with a sell rating, eight have given a hold rating and four have assigned a buy rating to the stock. According to MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $23.08.

Kenvue Price Performance

Shares of KVUE opened at $19.78 on Friday. The firm has a 50-day simple moving average of $21.70 and a two-hundred day simple moving average of $21.95. The stock has a market cap of $37.93 billion, a PE ratio of 35.97, a P/E/G ratio of 2.05 and a beta of 1.45. Kenvue Inc. has a 1-year low of $17.67 and a 1-year high of $24.46. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.00 and a quick ratio of 0.69.

Kenvue (NYSE:KVUE) last posted its earnings results on Thursday, February 6th. The company reported $0.26 earnings per share for the quarter, meeting the consensus estimate of $0.26. Kenvue had a net margin of 6.88% and a return on equity of 21.43%. As a group, analysts forecast that Kenvue Inc. will post 1.14 EPS for the current year.

Kenvue Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Wednesday, February 26th. Investors of record on Wednesday, February 12th will be paid a dividend of $0.205 per share. This represents a $0.82 annualized dividend and a yield of 4.15%. The ex-dividend date of this dividend is Wednesday, February 12th. Kenvue’s payout ratio is 149.09%.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.